Just amplifying what Rog has said in his post Getting the message.
As I have discussed previously, the Health Care Worker (HCW) market in the US is strategic for the uptake of QuantiFERON-TB Gold as a replacement for the TST. This data (and the comments by HCWs) clearly shows that the trend is moving strongly towards a preference of QFT for the diagnosis of Latent TB in this important market.
Whilst I would not call this a "tipping point" (for that we want to see an actual sales volume spike), I would suggest that this is a seminal event.
No comments:
Post a Comment